51午夜精品免费视频,亚洲中少妇久久中文字幕

Efegatran sulfate

NMR下載 COA and HPLC MSDS下載
names：
(S)-1-(N-((S)-5-guanidino-1-oxopentan-2-yl)-N-methyl-D-phenylalanyl)pyrrolidine-2-carboxamide sulfate
CAS號：
126721-07-1
MDL Number：
MF(分子式)： C21H34N6O7S MW(分子量)： 514.59
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫存描述	數(shù)量	總計(jì) (￥)

大包裝詢價(jià) 提供各種包裝，敬請垂詢
收藏商品商品點(diǎn)評加入購物車立即購買

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準(zhǔn)確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	Efegatran sulfate
英文別名	Efegatran sulfate; LY294468 sulfate; LY 294468 sulfate; LY-294468 sulfate;
CAS號	126721-07-1
Inchi	InChI=1S/C21H32N6O3.H2O4S/c1-26(16(14-28)9-5-11-25-21(23)24)18(13-15-7-3-2-4-8-15)20(30)27-12-6-10-17(27)19(22)29;1-5(2,3)4/h2-4,7-8,14,16-18H,5-6,9-13H2,1H3,(H2,22,29)(H4,23,24,25);(H2,1,2,3,4)/t16-,17-,18+;/m0./s1
InchiKey	VQRNSOAWJKHUJL-WSLRHHBVSA-N
分子式 Formula	C21H34N6O7S
分子量 Molecular Weight	514.59
溶解度Solubility
性狀	Solid powder
儲(chǔ)藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說明	Efegatran sulfate(CAS:126721-07-1):僅限應(yīng)用于工業(yè)或者科學(xué)研究過程中非醫(yī)療目的，不應(yīng)用于人類或動(dòng)物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。
Introduction	Efegatran sulfate is an antithrombotic.
Application1
Application2
Application3

警示圖
危險(xiǎn)性	Warning
危險(xiǎn)性警示
安全聲明
安全防護(hù)
備注

[1]Fung AY, Lorch G, Cambier PA, Hansen D, Titus BG, Martin JS, Lee JJ, Every NR, Hallstrom AP, Stock-Novack D, Scherer J, Weaver WD. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators. Am Heart J. 1999 Oct;138(4 Pt 1):696-704. PubMed PMID: 10502216.

[2]PRIME Investigators. Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. Am Heart J. 2002 Jan;143(1):95-105. PubMed PMID: 11773918.

[3] Lijnen HR. Efegatran. Institute for drug research/IVAX. IDrugs. 2001 Jun;4(6):691-4. PubMed PMID: 16001314.

[4] Klootwijk P, Lenderink T, Meij S, Boersma H, Melkert R, Umans VA, Stibbe J, Müller EJ, Poortermans KJ, Deckers JW, Simoons ML. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J. 1999 Aug;20(15):1101-11. PubMed PMID: 10413640.

[5] Smith GF, Shuman RT, Craft TJ, Gifford DS, Kurz KD, Jones ND, Chirgadze N, Hermann RB, Coffman WJ, Sandusky GE, Roberts E, Jackson CV. A family of arginal thrombin inhibitors related to efegatran. Semin Thromb Hemost. 1996;22(2):173-83. PubMed PMID: 8807715.

6: Shetler TJ, Crowe VG, Bailey BD, Jackson CV. Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis. Circulation. 1996 Oct 1;94(7):1719-25. PubMed PMID: 8840866.7: Callas DD, Hoppensteadt D, Fareed J. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin. Semin Thromb Hemost. 1995;21(2):177-83. PubMed PMID: 7660140.8: Sanderson PE, Naylor-Olsen AM. Thrombin inhibitor design. Curr Med Chem. 1998 Aug;5(4):289-304. Review. PubMed PMID: 9668196.9: Tarzami ST, Wang G, Li W, Green L, Singh JP. Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells. J Thromb Haemost. 2006 Mar;4(3):656-63. PubMed PMID: 16460448.10: Kaiser B, Koza M, Walenga JM, Fareed J. Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood. Thromb Res. 1996 May 1;82(3):257-63. PubMed PMID: 8732629.1

對不起，暫無產(chǎn)品評價(jià)！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開